Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV

被引:44
作者
Buckner, C
Gines, LG
Saunders, CJ
Vojtech, L
Srivastava, I
Gettie, A
Bohm, R
Blanchard, J
Barnett, SW
Safrit, JT
Stamatatos, L
机构
[1] Univ Washington, Seattle Biomed Res Inst, Dept Pathobiol, Seattle, WA 98109 USA
[2] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
[3] Chiron Corp, Emeryville, CA 94608 USA
[4] Tulane Reg Primate Res Ctr, Covington, LA 70433 USA
[5] Emory Univ, Sch Med, Atlanta, GA 30329 USA
关键词
HIV neutralization; SHIVSF162P4; DNA immunization; Delta V2gp140; CD8+depletion; Macaques; CTL; antibodies;
D O I
10.1016/j.virol.2003.12.003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The potential of vaccine-elicited anti-HIV envelope antibodies to control HIV-infection was evaluated by immunizing macaques with the HIV envelope protein and transiently depleting them of their CD8+ cells before intravenous challenge with the pathogenic CCR5-tropic SIV/HIV chimeric virus, SHIVSF162P4. Although sterilizing immunity was not achieved, all vaccinated animals effectively controlled infection and remained free of disease for the duration of observation (over 3 years). In contrast, during the same period, the control animals progressed to disease. Both the vaccinees and the controls developed robust cell-mediated antiviral and neutralizing antibody responses following infection. A comparative analysis of these responses suggests that the more effective long-term control of infection by the vaccinated animals is due to the more rapid development of anti-HIV envelope antibodies. These studies suggest that priming by vaccination of B cell anti-HIV envelope responses maybe crucial for the long-term control of HIV infection. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:167 / 180
页数:14
相关论文
共 52 条
[1]   Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine [J].
Amara, RR ;
Smith, JM ;
Staprans, SI ;
Montefiori, DC ;
Villinger, F ;
Altman, JD ;
O'Neil, SP ;
Kozyr, NL ;
Xu, Y ;
Wyatt, LS ;
Earl, PL ;
Herndon, JG ;
McNicholl, JM ;
McClure, HM ;
Moss, B ;
Robinson, HL .
JOURNAL OF VIROLOGY, 2002, 76 (12) :6138-6146
[2]   Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines [J].
Amara, RR ;
Villinger, F ;
Staprans, SI ;
Altman, JD ;
Montefiori, DC ;
Kozyr, NL ;
Xu, Y ;
Wyatt, LS ;
Earl, PL ;
Herndon, JG ;
McClure, HM ;
Moss, B ;
Robinson, HL .
JOURNAL OF VIROLOGY, 2002, 76 (15) :7625-7631
[3]  
AMARA RR, 2001, SCIENCE, V8, P8
[4]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[5]   The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region [J].
Barnet, SW ;
Lu, S ;
Srivastava, I ;
Cherpelis, S ;
Gettie, A ;
Blanchard, J ;
Wang, S ;
Mboudjeka, I ;
Leung, L ;
Lian, Y ;
Fong, A ;
Buckner, C ;
Ly, A ;
Hilt, S ;
Ulmer, J ;
Wild, CT ;
Mascola, JR ;
Stamatatos, L .
JOURNAL OF VIROLOGY, 2001, 75 (12) :5526-5540
[6]   Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys [J].
Barouch, DH ;
Kunstman, J ;
Glowczwskie, J ;
Kunstman, KJ ;
Egan, MA ;
Peyerl, FW ;
Santra, S ;
Kuroda, MJ ;
Schmitz, JE ;
Beaudry, K ;
Krivulka, GR ;
Lifton, MA ;
Gorgone, DA ;
Wolinsky, SM ;
Letvin, NL .
JOURNAL OF VIROLOGY, 2003, 77 (13) :7367-7375
[7]   Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination [J].
Barouch, DH ;
Santra, S ;
Schmitz, JE ;
Kuroda, MJ ;
Fu, TM ;
Wagner, W ;
Bilska, M ;
Craiu, A ;
Zheng, XX ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Nickerson, CE ;
Trigona, WL ;
Punt, K ;
Freed, DC ;
Guan, LM ;
Dubey, S ;
Casimiro, D ;
Simon, A ;
Davies, ME ;
Chastain, M ;
Strom, TB ;
Gelman, RS ;
Montefiori, DC ;
Lewis, MG ;
Emini, EA ;
Shiver, JW ;
Letvin, NL .
SCIENCE, 2000, 290 (5491) :486-492
[8]   Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes [J].
Barouch, DH ;
Kunstman, J ;
Kuroda, MJ ;
Schmitz, JE ;
Santra, S ;
Peyerl, FW ;
Krivulka, GR ;
Beaudry, K ;
Lifton, MA ;
Gorgone, DA ;
Montefiori, DC ;
Lewis, MG ;
Wolinsky, SM ;
Letvin, NL .
NATURE, 2002, 415 (6869) :335-339
[9]  
Bjorndal A, 1997, J VIROL, V71, P7478
[10]   Antibodies, viruses and vaccines [J].
Burton, DR .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (09) :706-713